Longevity Biomedical, a biopharmaceutical company focused on advancing new technologies across therapeutics, agreed to go public via a SPAC merger with Denali Capital Acquisition in $236m deal. "Longevity Biomedical is dedicated to advancing science-driven solutions to improve human health. This business combination will provide the platform to advance cutting-edge technologies spanning multiple areas of unmet medical need for the aging population. The proceeds from this transaction will allow Longevity to reach significant clinical development milestones for our four leading technologies that have demonstrated successful results in clinical studies. In addition, Longevity will retain an opportunistic, visionary approach to future health advancements in the areas of health monitoring and digital health solutions," Bradford A. Zakes, Longevity Biomedical CEO.